| Identification | Back Directory | [Name]
ZD 9379 | [CAS]
170142-20-8 | [Synonyms]
ZD 9379
7-CHLORO-2,3-DIHYDRO-2-(4-METHOXY-2-METHYLPHENYL)PYRIDAZINO [4,5-B] QUINOLINE-1,4,10(5H)TRIONE
Pyridazino[4,5-b]quinoline-1,4,10(5H)-trione, 7-chloro-2,3-dihydro-2-(4-methoxy-2-methylphenyl)- | [Molecular Formula]
C19H14ClN3O4 | [MDL Number]
MFCD27991266 | [MOL File]
170142-20-8.mol | [Molecular Weight]
383.79 |
| Chemical Properties | Back Directory | [density ]
1.54±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
<19.19mg/ml in DMSO; <7.68mg/ml in 1eq. NaOH | [pka]
9.25±0.20(Predicted) |
| Hazard Information | Back Directory | [Uses]
7-Chloro-2,3-dihydro-2-(4-methoxy-2-methylphenyl)pyridazino[4,5-b]quinoline-1,4,10(5H)-trione is a N-methyl-D-aspartate receptor antagonist and a neuroprotective agent. | [in vivo]
ZD-9379 (5 mg/kg) reduces number of spreading depressions and infarct size in rats with permanent middle cerebral artery occlusion[1]. | Animal Model: | Male Sprague-Dawley rats weighing 290 to 340 g undergoing permanent middle cerebral artery occlusion (MCAO)[1] | | Dosage: | 5 mg/kg | | Administration: | Group1: a 5-mg/kg bolus of ZD-9379 over 5 minutes followed by 5 mg/kg per hour drug infusion for 4 hours beginning 30 minutes before MCAO.
Group 2: (post-MCAO treatment group), a 5-mg/kg bolus of ZD-9379 30 minutes after MCAO followed by 5 mg/kg per hour drug infusion for 4 hours. | | Result: | Initiated before or after MCAO significantly reduced the number of Spreading depressions (SDs) and infarct volume in a permanent focal ischemia model.
|
|
|
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
| Company Name: |
Alomone Labs
|
| Tel: |
4008-168-068 13121892008 |
| Website: |
www.alomone.com |
|